Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 4
1997 2
1998 4
1999 3
2000 2
2001 3
2002 16
2003 46
2004 113
2005 151
2006 201
2007 255
2008 304
2009 284
2010 287
2011 325
2012 304
2013 315
2014 305
2015 318
2016 351
2017 356
2018 358
2019 341
2020 299
2021 369
2022 338
2023 160

Text availability

Article attribute

Article type

Publication date

Search Results

5,169 results

Results by year

Filters applied: . Clear all
Page 1
Aripiprazole.
Prommer E. Prommer E. Am J Hosp Palliat Care. 2017 Mar;34(2):180-185. doi: 10.1177/1049909115612800. Epub 2016 Jul 10. Am J Hosp Palliat Care. 2017. PMID: 26589880 Review.
Third-generation atypical antipsychotic drugs have emerged as a potential choice for delirium management. Aripiprazole is a third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics. Aripiprazole act …
Third-generation atypical antipsychotic drugs have emerged as a potential choice for delirium management. Aripiprazole is a third-gen …
A safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A, Shapiro BB. Preda A, et al. Expert Opin Drug Saf. 2020 Dec;19(12):1529-1538. doi: 10.1080/14740338.2020.1832990. Epub 2020 Oct 16. Expert Opin Drug Saf. 2020. PMID: 33064050 Review.
AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the safety and efficacy of aripiprazole in adults with schizophrenia. Formulations of aripiprazole reviewed include oral aripipraz …
AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the saf …
Classics in Chemical Neuroscience: Aripiprazole.
Casey AB, Canal CE. Casey AB, et al. ACS Chem Neurosci. 2017 Jun 21;8(6):1135-1146. doi: 10.1021/acschemneuro.7b00087. Epub 2017 Apr 13. ACS Chem Neurosci. 2017. PMID: 28368577 Free PMC article. Review.
New observations, however, link aripiprazole to compulsive behaviors in a small group of patients, an unusual side effect for antipsychotics. In this review, we discuss the chemical synthesis, pharmacology, pharmacogenomics, drug metabolism, and adverse events of aripip …
New observations, however, link aripiprazole to compulsive behaviors in a small group of patients, an unusual side effect for antipsy …
Drug safety evaluation of aripiprazole in bipolar disorder.
Cuomo A, Beccarini Crescenzi B, Goracci A, Bolognesi S, Giordano N, Rossi R, Facchi E, Neal SM, Fagiolini A. Cuomo A, et al. Expert Opin Drug Saf. 2019 Jun;18(6):455-463. doi: 10.1080/14740338.2019.1617847. Epub 2019 May 17. Expert Opin Drug Saf. 2019. PMID: 31072228 Review.
Areas covered: The authors reviewed aripiprazole safety in bipolar disorder according to product labeling. English language reports located through PubMed and information available on the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) websites, w …
Areas covered: The authors reviewed aripiprazole safety in bipolar disorder according to product labeling. English language reports l …
Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.
Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Ribeiro ELA, et al. Eur J Clin Pharmacol. 2018 Oct;74(10):1215-1233. doi: 10.1007/s00228-018-2498-1. Epub 2018 Jun 15. Eur J Clin Pharmacol. 2018. PMID: 29905899 Review.
RESULTS: Fourteen studies fulfilled the inclusion criteria. Aripiprazole showed efficacy similar to that of both typical and atypical antipsychotic drugs (except olanzapine and amisulpride). Aripiprazole caused significantly lower weight gain and alterations in gluc …
RESULTS: Fourteen studies fulfilled the inclusion criteria. Aripiprazole showed efficacy similar to that of both typical and atypical …
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Boettger S, Jenewein J, Breitbart W. Boettger S, et al. Palliat Support Care. 2015 Aug;13(4):1079-85. doi: 10.1017/S1478951514001059. Epub 2014 Sep 5. Palliat Support Care. 2015. PMID: 25191793 Free article.
RESULTS: The baseline characteristics of the medication groups were not different: The mean age of the patients ranged from 64.0 to 69.6 years, dementia was present in between 23.8 and 28.6%, and baseline MDAS scores were 19.9 (haloperidol), 18.6 (risperidone), 19.4 (olanzapine), …
RESULTS: The baseline characteristics of the medication groups were not different: The mean age of the patients ranged from 64.0 to 69.6 yea …
Aripiprazole-Associated Oligospermia.
Garip B, Oğur B, Uzun O. Garip B, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e725-e726. doi: 10.1097/MJT.0000000000001246. Epub 2020 Oct 1. Am J Ther. 2022. PMID: 33021544 No abstract available.
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
Sommi RW, Rege B, Wehr A, Faldu S, Du Y, Weiden PJ. Sommi RW, et al. CNS Spectr. 2022 Jun;27(3):262-267. doi: 10.1017/S1092852920002072. Epub 2020 Dec 3. CNS Spectr. 2022. PMID: 33267924 Review.
Aripiprazole lauroxil (AL) is a long-acting atypical antipsychotic approved for the treatment of schizophrenia in adults. ...The relationship between dosage strength (milligram injected), injection interval (time between injection visits), and expected steady-state plasma …
Aripiprazole lauroxil (AL) is a long-acting atypical antipsychotic approved for the treatment of schizophrenia in adults. ...The rela …
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd. Lenze EJ, et al. Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Lancet. 2015. PMID: 26423182 Free PMC article. Clinical Trial.
FINDINGS: From July 20, 2009, to Dec 30, 2013, we recruited 468 eligible participants, 181 (39%) of whom did not remit and were randomly assigned to aripiprazole (n=91) or placebo (n=90). A greater proportion of participants in the aripiprazole group achieved remiss …
FINDINGS: From July 20, 2009, to Dec 30, 2013, we recruited 468 eligible participants, 181 (39%) of whom did not remit and were randomly ass …
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.
Hart XM, Hiemke C, Eichentopf L, Lense XM, Clement HW, Conca A, Faltraco F, Florio V, Grüner J, Havemann-Reinecke U, Molden E, Paulzen M, Schoretsanitis G, Riemer TG, Gründer G. Hart XM, et al. Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391. doi: 10.1007/s00213-022-06233-2. Epub 2022 Oct 5. Psychopharmacology (Berl). 2022. PMID: 36195732 Free PMC article. Review.
METHODS: The relevant literature was systematically searched and reviewed for aripiprazole oral and injectable formulations. Population-based concentration ranges were computed (N = 3,373) and pharmacokinetic influences investigated. ...We suggest a therapeutic reference r …
METHODS: The relevant literature was systematically searched and reviewed for aripiprazole oral and injectable formulations. Populati …
5,169 results